Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Surgery confers multiple downstream benefits: Lower rates of obesity-related comorbidities (like hypertension, hyperlipidemia, sleep apnea) compared to GLP-1 therapy at follow-up JAMA Network Reduced health care utilization: fewer inpatient stays, outpatient visits, and ED visits per patient per month post-surgery compared to GLP-1 therapy
The study, which tested the drug in 529 patients with obesity and heart failure with preserved ejection fraction (HFpEF), demonstrated a 16.6-point increase at 52 weeks, with regard to the Clinical Summary Score (CSS) on the Kansas City Cardiomyopathy Questionnaire (KCCQ) a measure of symptoms of heart failure in comparison to an 8.7-point increase in the placebo group
Authored by: Vikram Gosain and Meenu Grover The global conversation around obesity is undergoing a seismic shift
As always, you can use our black and white images to have students highlight water on the landscape
